Semaglutide vs Phentermine for Weight Loss: How They Compare

The quick answer: Semaglutide is a GLP-1 receptor agonist — an injectable (and now oral) drug FDA-approved for long-term, chronic weight management, producing the larger weight loss but at meaningfully higher cost. Phentermine is a stimulant appetite suppressant — a cheap, oral, generic Schedule IV controlled substance FDA-approved for short-term use (generally up to 12 weeks). More weight loss and durability favor semaglutide; cost, speed, and access often favor phentermine. The right answer is patient-specific.

The quick answer for busy clinicians

If a colleague asks “semaglutide or phentermine?” in a hallway, the honest one-sentence version is this: reach for semaglutide when you are treating obesity as a chronic disease that needs durable, year-over-year management, and reach for phentermine when you want an inexpensive, fast short-term jump-start for a motivated patient who does not need — or cannot afford — long-term pharmacotherapy.

Everything else in this comparison is detail beneath that headline. Semaglutide delivers more weight loss and, uniquely, an FDA-approved indication for ongoing use, which matters because obesity behaves like a chronic relapsing disease rather than a problem you fix once. Phentermine is the most commonly prescribed appetite suppressant in the country for a reason: it works, it is familiar, and it costs almost nothing. The two are not interchangeable, and a good weight-loss practice keeps both on the shelf.

How each one works

The clearest way to understand the difference is mechanistically. These drugs do not just differ in strength — they act on entirely separate systems.

Semaglutide: incretin biology and satiety

Semaglutide is a GLP-1 receptor agonist. It imitates glucagon-like peptide-1, a gut hormone released in response to food, and activates GLP-1 receptors distributed throughout the body. The weight effect runs through several parallel mechanisms: it activates satiety centers in the hypothalamus so patients feel full sooner and stay full longer, it slows gastric emptying, it modulates reward pathways so calorie-dense foods feel less compelling, and it stabilizes post-meal glucose and insulin. Many patients describe the constant intrusive thoughts about food — “food noise” — quieting within the first weeks. For a deeper treatment of the mechanism, see our clinical overview of semaglutide and the broader class of GLP-1 medications for weight loss.

Phentermine: sympathomimetic appetite suppression

Phentermine is a stimulant that belongs to a class of drugs called sympathomimetic amines. Rather than mimicking a satiety hormone, it works upstream in the central nervous system: it triggers the release of norepinephrine, dopamine, and serotonin, which suppresses appetite and modestly increases energy expenditure. The result is that patients simply feel less hungry. It is a fast, direct effect — appetite suppression that begins quickly — but it is a stimulant effect, which is exactly why phentermine carries stimulant-class cautions and is reserved for short-term use. Our full phentermine overview covers its profile in detail.

The mechanistic contrast matters clinically: a satiety-hormone agonist and a central stimulant produce different side-effect profiles, different cardiovascular considerations, and different rules about how long a patient can stay on the drug.

FDA status and duration of use

This is where the two diverge most sharply, and it is the distinction providers most often blur.

Semaglutide is FDA-approved for chronic weight management as Wegovy, used alongside reduced-calorie diet and increased physical activity. “Chronic” is the operative word: it is designed and labeled for ongoing, long-term use, consistent with treating obesity as a chronic disease. Trial data show that patients who continue therapy tend to maintain their loss, while those who stop tend to regain a substantial portion — which is why it is framed as a maintenance therapy, not a temporary course.

Phentermine is FDA-approved for short-term use, generally no longer than 12 weeks (some studies extend to about six months), and it is a Schedule IV controlled substance — meaning it has a proven but low potential for abuse and an accepted medical use. Because it is controlled, prescribing it carries DEA compliance obligations that semaglutide does not. The short-term ceiling is not bureaucratic fine print; it reflects the drug's stimulant pharmacology and the way appetite-suppressant effects tend to wane over time.

Efficacy: the honest magnitude difference

On raw weight loss, the gap is real and it favors semaglutide — but the numbers deserve honest framing rather than hype.

Semaglutide for chronic weight management has been evaluated in clinical trials extending up to 68 weeks, with patients losing on the order of 15 percent of initial body weight, and semaglutide has been associated with up to roughly 16 percent weight loss over placebo. That is a substantial advance for a field where durable pharmacologic options have historically been limited.

Phentermine produces meaningful but smaller loss: on the order of about 3 percent of initial body weight at three months and 5 to 7 percent at six months. That is a clinically useful result for a short-term, low-cost agent — but it is roughly half to a third of what semaglutide achieves over a longer horizon, and phentermine's effect is studied over a much shorter window.

Two honesty caveats belong here. First, the comparison is not perfectly apples-to-apples: semaglutide's figures come from long trials of sustained use, while phentermine's come from short courses, because that is how each drug is actually used. Second, with any short-term agent, durability is the weak point — short-term weight loss is common, but the majority of patients regain weight over the following years unless the underlying behavior and physiology are addressed. Semaglutide's larger numbers come with their own asterisk: stopping the drug tends to reverse the benefit. Neither drug is a cure; both work within a program of diet, activity, and monitoring.

Semaglutide vs phentermine at a glance

	Semaglutide	Phentermine
Drug class	GLP-1 receptor agonist (incretin mimetic peptide)	Sympathomimetic amine (CNS stimulant)
Mechanism	Activates GLP-1 receptors — increases satiety, slows gastric emptying, improves glucose handling	Releases norepinephrine, dopamine & serotonin to suppress appetite and modestly raise energy expenditure
FDA use & duration	Approved for chronic / long-term weight management (Wegovy); designed for ongoing use	Approved for short-term use, generally ≤12 weeks; Schedule IV controlled substance
Typical weight loss	~15% of body weight over ~68 weeks (up to ~16% vs placebo)	~3% at 3 months; ~5–7% at 6 months
Cost & access	Expensive — often several hundred to >$1,000/month branded; coverage can be difficult	Cheap — old generic, often a few dollars/month cash-pay
Key risks / cautions	GI effects (nausea, vomiting); pancreatitis risk; boxed warning re: thyroid C-cell tumors; lean-mass loss	Stimulant effects — raised heart rate/blood pressure, insomnia; controlled-substance & DEA compliance; short-term cap

The table makes the trade-off legible: semaglutide wins on magnitude and durability of weight loss and on long-term indication; phentermine wins decisively on cost, speed, and simplicity. Neither column is “the loser.”

Cost and access: the practical deciders

In the real world, efficacy rarely decides the prescription on its own — cost and access do. This is where phentermine and semaglutide are furthest apart.

Phentermine is inexpensive. It is an old, widely available generic that frequently costs only a few dollars a month cash-pay, with no prior authorization to fight. For a patient without coverage, or a cash-pay weight-management practice that wants an accessible first-line option, that price point is a genuine advantage — part of why it remains the most commonly prescribed appetite suppressant.

Semaglutide is expensive. Branded GLP-1 therapy often runs several hundred to over a thousand dollars a month without coverage, and insurance approval specifically for weight management (as opposed to diabetes) can be difficult to secure. For many patients, that cost — not the science — is the deciding factor. Compounded semaglutide exists in part because of these access pressures, but it sits in a far more complicated and shifting regulatory position than the approved branded product, and any clinician considering it must understand the current rules before acting.

The practical upshot: a provider who only stocks the expensive option leaves behind the patients who cannot reach it, and a provider who only offers the cheap short-term option cannot serve patients who need durable chronic management. A mature weight-loss practice prices and positions both.

How providers choose — and combine

Matching the drug to the patient is the actual clinical skill, and it rests on a handful of questions rather than a single ranking.

• Is this chronic management or a short-term jump-start? Long-term obesity management points toward semaglutide; a brief, motivated push points toward phentermine.
• What can the patient afford and access? Cost and coverage frequently override the efficacy comparison entirely.
• What is the cardiovascular and comorbidity picture? A stimulant carries different cautions than a GLP-1 agonist; screening drives the choice.
• What are the contraindications? Phentermine's controlled-substance status and stimulant profile, and semaglutide's thyroid C-cell boxed warning and GI profile, screen out different patients.
• How motivated and behaviorally ready is the patient? Short-term agents reward patients who can convert a quick win into lasting habits.

And the two are not always mutually exclusive. Within a structured, monitored program, clinicians sometimes combine agents that work through different mechanisms — a stimulant appetite suppressant and a GLP-1 agonist act on entirely separate pathways, so the rationale for layering them is coherent. But combination use is not a casual add-on: it demands careful patient selection, cardiovascular screening, respect for phentermine's controlled-substance and short-term limits, and close follow-up. Whether and how to combine therapies — and how to sequence a patient from a short-term agent into durable maintenance — is precisely the kind of judgment that structured training exists to build, not something to improvise from a comparison chart.

Training to prescribe both well

The reason this comparison resists a tidy “winner” is the same reason weight-loss prescribing rewards real education: the field is broad, the tools are different, and the skill is in the matching. A competent prescriber understands obesity as a disease, the full medication toolkit, the controlled-substance compliance phentermine requires, the side-effect and lean-mass considerations semaglutide brings, and the program-level judgment that decides when to use one, the other, or both in sequence.

Empire's curriculum is built around exactly that practical judgment, connecting the science on this page to dedicated medical weight loss training for providers who want to build or expand a weight-management practice responsibly.